Cargando…
Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy
Despite the remarkable successes of cancer immunotherapies, the majority of patients will experience only partial response followed by relapse of resistant tumors. While treatment resistance has frequently been attributed to clonal selection and immunoediting, comparisons of paired primary and relap...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489212/ https://www.ncbi.nlm.nih.gov/pubmed/36124553 http://dx.doi.org/10.7554/eLife.80315 |
_version_ | 1784792828563423232 |
---|---|
author | Gutwillig, Amit Santana-Magal, Nadine Farhat-Younis, Leen Rasoulouniriana, Diana Madi, Asaf Luxenburg, Chen Cohen, Jonathan Padmanabhan, Krishnanand Shomron, Noam Shapira, Guy Gleiberman, Annette Parikh, Roma Levy, Carmit Feinmesser, Meora Hershkovitz, Dov Zemser-Werner, Valentina Zlotnik, Oran Kroon, Sanne Hardt, Wolf-Dietrich Debets, Reno Reticker-Flynn, Nathan Edward Rider, Peleg Carmi, Yaron |
author_facet | Gutwillig, Amit Santana-Magal, Nadine Farhat-Younis, Leen Rasoulouniriana, Diana Madi, Asaf Luxenburg, Chen Cohen, Jonathan Padmanabhan, Krishnanand Shomron, Noam Shapira, Guy Gleiberman, Annette Parikh, Roma Levy, Carmit Feinmesser, Meora Hershkovitz, Dov Zemser-Werner, Valentina Zlotnik, Oran Kroon, Sanne Hardt, Wolf-Dietrich Debets, Reno Reticker-Flynn, Nathan Edward Rider, Peleg Carmi, Yaron |
author_sort | Gutwillig, Amit |
collection | PubMed |
description | Despite the remarkable successes of cancer immunotherapies, the majority of patients will experience only partial response followed by relapse of resistant tumors. While treatment resistance has frequently been attributed to clonal selection and immunoediting, comparisons of paired primary and relapsed tumors in melanoma and breast cancers indicate that they share the majority of clones. Here, we demonstrate in both mouse models and clinical human samples that tumor cells evade immunotherapy by generating unique transient cell-in-cell structures, which are resistant to killing by T cells and chemotherapies. While the outer cells in this cell-in-cell formation are often killed by reactive T cells, the inner cells remain intact and disseminate into single tumor cells once T cells are no longer present. This formation is mediated predominantly by IFNγ-activated T cells, which subsequently induce phosphorylation of the transcription factors signal transducer and activator of transcription 3 (STAT3) and early growth response-1 (EGR-1) in tumor cells. Indeed, inhibiting these factors prior to immunotherapy significantly improves its therapeutic efficacy. Overall, this work highlights a currently insurmountable limitation of immunotherapy and reveals a previously unknown resistance mechanism which enables tumor cells to survive immune-mediated killing without altering their immunogenicity. |
format | Online Article Text |
id | pubmed-9489212 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-94892122022-09-21 Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy Gutwillig, Amit Santana-Magal, Nadine Farhat-Younis, Leen Rasoulouniriana, Diana Madi, Asaf Luxenburg, Chen Cohen, Jonathan Padmanabhan, Krishnanand Shomron, Noam Shapira, Guy Gleiberman, Annette Parikh, Roma Levy, Carmit Feinmesser, Meora Hershkovitz, Dov Zemser-Werner, Valentina Zlotnik, Oran Kroon, Sanne Hardt, Wolf-Dietrich Debets, Reno Reticker-Flynn, Nathan Edward Rider, Peleg Carmi, Yaron eLife Cancer Biology Despite the remarkable successes of cancer immunotherapies, the majority of patients will experience only partial response followed by relapse of resistant tumors. While treatment resistance has frequently been attributed to clonal selection and immunoediting, comparisons of paired primary and relapsed tumors in melanoma and breast cancers indicate that they share the majority of clones. Here, we demonstrate in both mouse models and clinical human samples that tumor cells evade immunotherapy by generating unique transient cell-in-cell structures, which are resistant to killing by T cells and chemotherapies. While the outer cells in this cell-in-cell formation are often killed by reactive T cells, the inner cells remain intact and disseminate into single tumor cells once T cells are no longer present. This formation is mediated predominantly by IFNγ-activated T cells, which subsequently induce phosphorylation of the transcription factors signal transducer and activator of transcription 3 (STAT3) and early growth response-1 (EGR-1) in tumor cells. Indeed, inhibiting these factors prior to immunotherapy significantly improves its therapeutic efficacy. Overall, this work highlights a currently insurmountable limitation of immunotherapy and reveals a previously unknown resistance mechanism which enables tumor cells to survive immune-mediated killing without altering their immunogenicity. eLife Sciences Publications, Ltd 2022-09-20 /pmc/articles/PMC9489212/ /pubmed/36124553 http://dx.doi.org/10.7554/eLife.80315 Text en © 2022, Gutwillig et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Cancer Biology Gutwillig, Amit Santana-Magal, Nadine Farhat-Younis, Leen Rasoulouniriana, Diana Madi, Asaf Luxenburg, Chen Cohen, Jonathan Padmanabhan, Krishnanand Shomron, Noam Shapira, Guy Gleiberman, Annette Parikh, Roma Levy, Carmit Feinmesser, Meora Hershkovitz, Dov Zemser-Werner, Valentina Zlotnik, Oran Kroon, Sanne Hardt, Wolf-Dietrich Debets, Reno Reticker-Flynn, Nathan Edward Rider, Peleg Carmi, Yaron Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy |
title | Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy |
title_full | Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy |
title_fullStr | Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy |
title_full_unstemmed | Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy |
title_short | Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy |
title_sort | transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy |
topic | Cancer Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489212/ https://www.ncbi.nlm.nih.gov/pubmed/36124553 http://dx.doi.org/10.7554/eLife.80315 |
work_keys_str_mv | AT gutwilligamit transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT santanamagalnadine transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT farhatyounisleen transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT rasoulounirianadiana transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT madiasaf transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT luxenburgchen transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT cohenjonathan transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT padmanabhankrishnanand transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT shomronnoam transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT shapiraguy transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT gleibermanannette transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT parikhroma transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT levycarmit transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT feinmessermeora transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT hershkovitzdov transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT zemserwernervalentina transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT zlotnikoran transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT kroonsanne transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT hardtwolfdietrich transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT debetsreno transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT retickerflynnnathanedward transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT riderpeleg transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy AT carmiyaron transientcellincellformationunderliestumorrelapseandresistancetoimmunotherapy |